Stock screenerAll disclosures →
EDGAR →
PRME
Conviction 19HealthcareScan · Mon, Aug 10, 2026PRME$3.17+2.76%
ResistanceSupportVol 14Vol MA14 2.77M
May 11May 28Jun 16Jul 6Jul 23Aug 10
Price3.17
Change+2.76%
Gap+0.00%
Rel volume1.74×
Avg volume2.94M
Avg $ vol9.1M
SMA 203.08
SMA 503.27
SMA 2003.63
Price vs 50-3.15%
Price vs 200-12.85%
MA stackbearish
50/200 cross—
Supertrenddown · 3.49
RSI (14)50
MACD hist0.01
MACD crossbull · 0d
Stoch %K / %D75 / 66
ADX (14)13
+DI / −DI27 / 22
RSI divergence—
MACD divergenceBullish
ATR %+7.43%
ADR %5.96%
52w high6.67
52w low2.70
From 52w high-52.55%
Above 52w low+17.22%
New 52w highNo
SqueezeOn · 1d
Bollinger width20.88%
%B0.63
Donchian pos52.98%
Donchian high3.56
Donchian low2.72
AVWAP (52w high)3.88
vs AVWAP high-18.39%
AVWAP (52w low)3.45
vs AVWAP low-8.19%
OBV trendFlat
Chaikin MF (20)-0.03
Today vs 20d1.74×
Avg vol (14d)2.77M
Avg vol (20d)2.94M
Avg $ vol (20d)9.1M
Market cap574.06M
RS 3m (vs SPY)-6.82%
RS 6m (vs SPY)-19.05%
RS line new highNo
Trend template0/8
Technical rank22.8
1 week+12.63%
1 month-16.27%
3 months-1.40%
6 months-11.34%
1 year-13.99%
YTD-10.34%
P/E-2.85
P/B14.42
P/S123.93
P/FCF-3.44
EPS-1.35
Div yield—
ROE-505.27%
ROA-80.77%
Debt/Eq—
Current3.05
EV/EBITDA-2.62
Gross margin—
Net margin—
Rev growth55.28%
EPS growth-2.69%
Price target7.60
Target upside140.13%
Analyst ratingBuy
Institutional52.27%
Ent. value526.61M
Revenue1.23M
Net income-42.11M
Gross profit—
Free cash flow-167.09M
IndustryBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
ExchangeNasdaq
Shares out180.62M
Employees146
ListedThu, Oct 20, 2022
Free float69.86M
Float %38.7%
Short interest33.54M
Days to cover6.7d
Short volume53.6%
Squeeze score85 / 100
Next earnings—
EPS forecast—
Last EPS vs est−$0.24 vs −$0.24
Last surprise0.0% beat
Setup gradeD
Conviction19 / 100
Pattern quality—
Tech rank22.8 / 100
Group rank86 / 100 · Leading
Status laneNo active setup
Setup direction—
Pattern family
Resistance4.57
Support2.79
Days since event—
Candle confirm—
News sentiment—
Financials as of Tue, Jun 30, 2026 · quarterly.
Congress activity
Disclosed STOCK Act trades in PRME
No recent disclosed trades by Congress in PRME. STOCK Act filings can lag the trade by up to 45 days.
Insider activity
SEC Form 4 transactions in PRME · 8 buys
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
Foster-Cheek Kaye I Director · Stock Option (right to buy) · 2026-06-05 | Grant | 75K | $0 | 2026-06-05 | 2026-06-08 |
Kelly Michael Aaron Director · Stock Option (right to buy) · 2026-06-05 | Grant | 75K | $0 | 2026-06-05 | 2026-06-08 |
NELSEN ROBERT Director · Stock Option (right to buy) · 2026-06-05 | Grant | 75K | $0 | 2026-06-05 | 2026-06-08 |
Cahill Thomas Director · Stock Option (right to buy) · 2026-06-05 | Grant | 75K | $0 | 2026-06-05 | 2026-06-08 |
Schenkein David P Director · Stock Option (right to buy) · 2026-06-05 | Grant | 75K | $0 | 2026-06-05 | 2026-06-08 |
Chung Wendy Director · Stock Option (right to buy) · 2026-06-05 | Grant | 75K | $0 | 2026-06-05 | 2026-06-08 |
Marrazzo Jeffrey D Director · Stock Option (right to buy) · 2026-06-05 | Grant | 75K | $0 | 2026-06-05 | 2026-06-08 |
Makhni Svetlana Ni Chief Financial Officer · Stock Option (right to buy) · 2026-04-16 | Grant | 800K | $0 | 2026-04-16 | 2026-04-17 |
SEC filings
EDGAR filings in PRME · 4 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.
Start free — 14-day full access →Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.